Description: Agenus Inc., a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases. Its technology portfolio consists of saponin adjuvant based technologies and heat shock protein based technologies. The company offers Oncophage vaccine for the treatment of renal cell carcinoma in patients at intermediate risk of recurrence. Its products under development include QS-21 Stimulon adjuvant, which is in Phase III clinical trials for the treatment of malaria, melanoma, non-small cell lung cancer, and shingles, as well as for the treatment of various infectious diseases, multiple cancer types, and Alzheimer's disease; and HerpV, a therapeutic vaccine candidate that is in Phase 2 clinical trial for the treatment of genital herpes. The company's products under development also comprise Prophage series of cancer vaccines, including R-series candidates in RCC, M-series candidates in melanoma, and G-series candidates in glioma. Its Prophage series of cancer vaccines were tested in Phase III clinical trials for the treatment of renal cell carcinoma and metastatic melanoma; and are in Phase I and Phase II clinical trials for various indications, and in Phase II clinical trials for the treatment of diagnosed and recurrent glioma. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Home Page: www.agenusbio.com
AGEN Technical Analysis
3 Forbes Road
Lexington,
MA
02421-7305
United States
Phone:
781 674 4400
Officers
| Name | Title |
|---|---|
| Dr. Garo H. Armen Ph.D. | Founder, Exec. Chairman & CEO |
| Ms. Christine M. Klaskin | VP of Fin., Principal Financial Officer & Principal Accounting Officer |
| Dr. Steven J. O'Day M.D., Ph.D. | Chief Medical Officer |
| Dr. Jennifer S. Buell Ph.D. | Pres & CEO of MiNK Therapeutics |
| Craig Winter | Chief Information Officer |
| Regina Grebla Ph.D. | VP of Investor Relations & Communications |
| Ms. Robin E. Abrams J.D. | Chief Legal Officer |
| Ms. Tracy Mazza Clemente | Chief People Officer |
| John Castle | Head of Translational Medicine & Bioinformatics |
| Ms. Julie DeSander | Chief Bus. Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 9.48 |
| Price-to-Book MRQ: | 218.6149 |
| Price-to-Sales TTM: | 8.2731 |
| IPO Date: | 2000-02-04 |
| Fiscal Year End: | December |
| Full Time Employees: | 441 |